Summary
In recent years there has been a growing interest in techniques capable of analyzing sparse data, particularly gathered during Phase III clinical trials, and there is now pressure on manufacturers to obtain more kinetic and dynamic information from Phase III studies. Techniques for the analysis of sparse data are reviewed drawing on a number of examples taken from pharmacokinetic and pharmacodynamic experiments.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Whiting B., Kelman A.W., Grevel J. (1986): Population pharmacokinetics. Theory and application. Clin. Pharmacokinet., 11, 387–401.
Aarons L. (1991): Population pharmacokinetics: theory and practice. Br. J. Clin. Pharmacol., 32, 669–670.
New Strategies in Drug Development and Clinical Evaluation: the Population Approach. (1992): Rowland M., Aarons L. (eds). Luxembourg, Commission of the European Communities.
Jochemsen R. (1992): Current experience of population pharmacokinetics within the pharmaceutical industry: an introduction. In: Rowland M., Aarons L. (eds). New Strategies in Drug Development and Clinical Evaluation: the Population Approach. Luxembourg, Commission of the European Communities, pp. 127–130.
Gibaldi M., Perrier D. (1982): Pharmacokinetics. 2nd edn. New York, Marcel Dekker.
Lindstrom F.T., Birkes D.S. (1984): Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model. Drug Met. Rev., 15, 195–264.
Ludden T., Allerheiligen S.R.B., Burk R.F. (1991): Application of population analysis to physiological pharmacokinetics. J. Pharmacokinet. Biopharm. (Suppl), 19, 101S-113S.
Driscoll M.S., Ludden T.M., Casto D.T., Littlefield L.C. (1989): Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. J. Pharmacokinet. Biopharm., 17, 141–168.
Kelman A.W., Thomson A.H., Whiting B., Bryson S.M., Steedman D.A. (1984): Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br. J. Clin. Pharmacol., 18, 685–692.
Moore E.S., Faix R.G., Banagale R.C., Grasela T.H. (1989): The population pharmacokinetics of theophylline in neonates and young infants. J. Pharmacokinet. Biopharm., 17, 47–66.
Aarons L. (1991): The kinetics of flurbiprofen in synovial fluid. J. Pharmacokinet. Biopharm., 19, 265–269.
Winstanley P.A., Watkins W.M. (1992): Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malaria. Br. J. Clin. Pharmacol., 33, 575–581.
Beal S.L., Sheiner L.B. (1982): Estimating population kinetics. CRC Crit. Rev. Biomed. Eng., 8, 195–222.
Amisaki T., Tatsuhara T. (1988): An alternative two stage method via the EM-algorithm for the estimation of population pharmacokinetic parameters. J. PharmacobioDyn., 11, 335–348.
Lindstrom M.J., Bates D.M. (1990): Nonlinear mixed effects models for repeated measures data. Biometrics, 46, 673–687.
Vonesh E.F., Carter R.L. (1992): Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics, 48, 1–17.
Mallet A. (1986): A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645–656.
Mallet A., Mentre F., Steimer J.-L., Lokiec F. (1988): Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J. Pharmacokinet. Biopharm., 16, 311–327.
Mallet A., Mentre F., Gilles J., et al. (1988): Handling covariates in population pharmacokinetics, with an application to gentamicin. Biomed. Meas. Inf. Cont., 2, 138–146.
Mentre F., Mallet A. (1992): Experiences with NPML — application to dosage individualisation of cyclosporine, gentamicin and zidovudine. In: Rowland M., Aarons L. (eds). New Strategies in Drug Development and Clinical Evaluation: the Population Approach. Luxembourg, Commission of the European Communities, pp. 75–88.
Schumitsky A. (1991): Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput., 45, 143–157.
Davidian M., Gallant A.R. (1992): Smooth nonparametric maximum likelihood estimation for population pharmacokinetics with application to quinidine. J. Pharmacokinet. Biopharm., 20, 529–556.
Racine-Poon A., Smith A.F.M. (1990): Population models. In: Berry D.A. (ed.) Statistical Methodology in the Pharmaceutical Sciences. New York, Marcel Dekker, pp. 139–162.
Racine-Poon A. (1992): A Bayesian approach to the prediction of the plasma concentration range of carbamazepine in epileptic patients. In: Rowland M., Aarons L. (eds.) New Strategies in Drug Development and Clinical Evaluation: the Population Approach. Luxembourg, Commission of the European Communities, pp. 91–98.
Sheiner L.B., Beal S.L. (1982): Bayesian individualisation of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci., 71, 1344–1348.
Vozeh S., Steiner C. (1987): Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis. J. Pharmacokinet. Biopharm., 15, 511–528.
Sanathanan L., Peck C., Temple R., Lieberman R., Pledger G. (1991): Randomization, pharmacokinetically-controlled dosing and titration: an integrated approach for designing clinical trials. Drug Inf. J., 25, 425–431.
Aarons L., Vozeh S., Wenk M., Weiss Ph., Follath F. (1989): Population pharmacokinetics of tobramycin. Br. J. Clin. Pharmacol., 28, 305–314.
Aarons L., Mandeman J.W., Danhof M. (1991): A population analysis of the pharmacokinetics of midazolam in the rat. J. Pharmacokinet. Biopharm., 19, 485–496.
Sheiner L.B., Benet L.Z. (1985): Premarketing observational studies of population pharmacokinetics of new drugs. Clin. Pharmacol. Ther., 38, 481–487.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aarons, L. Sparse data analysis. Eur. J. Drug Metab. Pharmacokinet. 18, 97–100 (1993). https://doi.org/10.1007/BF03220012
Issue Date:
DOI: https://doi.org/10.1007/BF03220012